ArticleGlycobiology2020
Identification of Tn antigen O-GalNAc-expressing glycoproteins in human carcinomas using novel anti-Tn recombinant antibodies.
Article in Glycobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 36 citations in OpenAlex.
- Using Synthetic Glycans to Investigate Anti-Glycan Antibodies and Explore Their Medical Potential.Angewandte Chemie (International ed. in English) · 2026Review
- Tumor glycosylation engages CD301b-mediated myeloid regulation in breast cancer.Research square · 2026Article
- The Critical Role of GALNTs-Regulated O-GalNAc Glycosylation in Cancer Malignancy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Structure-guided phage display discovery of antibodies for (S)Tn-glycans in protein context.Nature chemical biology · 2026Article
- CD301b lectin expression in the breast tumor microenvironment augments tumor growth.Research square · 2025Article
- CD301b lectin expression in the breast tumor microenvironment augments tumor growth.bioRxiv : the preprint server for biology · 2025Article
- Differential expression of CD175 and CA19-9 in pancreatic adenocarcinoma.Scientific reports · 2025Article
- Mammalian cell-based production of glycans, glycopeptides and glycomodules.Nature communications · 2024Article
- Cosmc regulates O-glycan extension in murine hepatocytes.Glycobiology · 2024Article
- Mass Spectrometry Strategies forCells · 2024Review
- Detection of Tn-antigen in breast and prostate cancer models by VVL-labeled red dye-doped nanoparticles.Nanomedicine (London, England) · 2024Article
- Large-Scale and Site-Specific Mapping of the Murine BrainAnalytical chemistry · 2023Article
- Review
- GermlineProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG.Scientific reports · 2023Article
- CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies.Frontiers in immunology · 2023Review
- Immunohistochemical analysis of Tn antigen expression in colorectal adenocarcinoma and precursor lesions.BMC cancer · 2022Article
- A Sweet Warning: Mucin-Type O-Glycans in Cancer.Cells · 2022Review
- Identification and characterization of circulating immune complexes in IgA nephropathy.Science advances · 2022Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
The Tn antigen is a neoantigen abnormally expressed in many human carcinomas and expression correlates with metastasis and poor survival. To explore its biomarker potential, new antibodies are needed that specifically recognize this antigen in tumors. Here we generated two recombinant antibodies to the Tn antigen, Remab6 as a chimeric human IgG1 antibody and ReBaGs6 as a murine IgM antibody and characterized their specificities using multiple biochemical and biological approaches. Both Remab6 and ReBaGs6 recognize clustered Tn structures, but most importantly do not recognize glycoforms of human IgA1 that contain potential cross-reactive Tn antigen structures. In flow cytometry and immunofluorescence analyses, Remab6 recognizes human cancer cell lines expressing the Tn antigen, but not their Tn-negative counterparts. In immunohistochemistry (IHC), Remab6 stains many human cancers in tissue array format but rarely stains normal tissues and then mostly intracellularly. We used these antibodies to identify several unique Tn-containing glycoproteins in Tn-positive Colo205 cells, indicating their utility for glycoproteomics in future biomarker studies. Thus, recombinant Remab6 and ReBaGs6 are useful for biochemical characterization of cancer cells and IHC of tumors and represent promising tools for Tn biomarker discovery independently of recognition of IgA1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.